How should rhabdomyolysis‑induced acute kidney injury with severe hyperbilirubinemia (creatine phosphokinase 35,000 U/L, creatinine 11 mg/dL, total bilirubin 16 mg/dL, direct bilirubin 14 mg/dL) be managed?

Management of Severe Rhabdomyolysis with AKI and Hyperbilirubinemia

This patient requires immediate initiation of renal replacement therapy (RRT) given the severe AKI (creatinine 11 mg/dL), life-threatening CPK elevation (35,000 U/L), and marked hyperbilirubinemia (total bilirubin 16 mg/dL with direct 14 mg/dL), as these parameters indicate multi-organ failure with high mortality risk.

Immediate RRT Initiation

Start continuous RRT (CRRT) emergently for this patient given the severe metabolic derangements and likely hemodynamic instability 1. The KDIGO guidelines recommend emergent RRT initiation for life-threatening changes in fluid, electrolyte, and acid-base balance 1. With a creatinine of 11 mg/dL and CPK of 35,000 U/L, this patient likely has:

• Refractory hyperkalemia (life-threatening)
• Severe metabolic acidosis
• Volume overload from aggressive fluid resuscitation
• Uremic complications

CRRT vs Intermittent Hemodialysis

Choose CRRT over intermittent hemodialysis in this critically ill patient 1. While RCTs haven't shown mortality benefit, CRRT is more physiologically appropriate for hemodynamically unstable patients and allows:

• Gradual fluid removal without precipitating hypotension
• Better myoglobin clearance through continuous filtration
• Stable electrolyte and acid-base management

Target effluent volume: 20-25 mL/kg/hour 1. This may require higher prescription volumes to achieve actual delivery.

Aggressive Fluid Resuscitation

Continue aggressive isotonic fluid resuscitation even while initiating RRT 2, 3. This remains the cornerstone of rhabdomyolysis management:

• Use isotonic saline or balanced crystalloid solutions 1, 2
• Add sodium bicarbonate given the likely metabolic acidosis and to alkalinize urine (target urine pH >6.5) 2
• The 2020 KDIGO conference notes ongoing investigation into balanced solutions versus 0.9% saline, but sodium bicarbonate is reasonable in patients with metabolic acidosis 1

Critical caveat: With creatinine 11 mg/dL, this patient likely already has significant volume overload from prior resuscitation attempts. RRT allows continued aggressive fluid administration while managing volume status.

Address the Hyperbilirubinemia Component

The severe hyperbilirubinemia (16 mg/dL with direct component 14 mg/dL) represents a second, concurrent cause of AKI 4. This 2025 study demonstrates that:

• Hyperbilirubinemia-associated AKI occurs through direct bile acid toxicity and tubular cast formation
• Bilirubin >20 mg/dL significantly increases AKI risk
• Renal recovery occurs at median 4.1 days after bilirubin decreases to median nadir of 4.19 mg/dL 4

Action steps:

1. Identify and treat the underlying cause of hyperbilirubinemia (cholestasis, hemolysis, hepatic dysfunction)
2. Consider that this patient has dual pathology: both myoglobin-induced tubular injury AND hyperbilirubinemia-associated AKI
3. The predominantly direct hyperbilirubinemia (14/16 mg/dL) suggests cholestatic or hepatocellular injury rather than hemolysis
4. Lowering bilirubin levels may result in AKI resolution even without definitive treatment 4

Advanced Extracorporeal Techniques

Consider dual concomitant CytoSorb hemoadsorption therapy if available 5. This 2025 case series showed:

• Two CytoSorb cartridges running in parallel enhanced myoglobin and cytokine clearance
• Marked improvements in CPK, renal, hepatic, and inflammatory markers
• Potential to contain rhabdomyolysis-related organ failure

This is particularly relevant given the combined severe rhabdomyolysis AND hyperbilirubinemia, as CytoSorb may help clear both myoglobin and inflammatory mediators contributing to multi-organ dysfunction 5.

Electrolyte and Metabolic Management

Monitor and aggressively treat:

• Hyperkalemia: Likely present and life-threatening; RRT provides definitive management
• Hypocalcemia: Common in rhabdomyolysis; treat only if symptomatic to avoid calcium-phosphate precipitation
• Hyperphosphatemia: Expected with this degree of muscle breakdown
• Metabolic acidosis: Managed with bicarbonate-containing fluids and RRT

Vascular Access for RRT

Place an uncuffed non-tunneled dialysis catheter 1:

• First choice: Right internal jugular vein
• Alternative: Femoral vein (though inferior if patient has increased body mass)
• Use appropriate length and gauge for CRRT

Use regional citrate anticoagulation for CRRT if no contraindications 1. This remains the 2012 KDIGO recommendation supported by existing data.

Monitoring Strategy

Serial monitoring every 6-12 hours:

• CPK levels (expect slow decline over days to weeks)
• Creatinine and urine output
• Electrolytes (K, Ca, Phos, Mg)
• Bilirubin levels (both total and direct)
• Acid-base status
• Volume status and fluid balance

CPK levels predict AKI severity but not mortality 6. With CPK >10,000 U/L, this patient has high risk for stage 3 AKI and RRT requirement, which has already manifested.

Prognosis and Recovery

Renal recovery expectations:

• Most patients with rhabdomyolysis-induced AKI have complete recovery of renal function 6
• Among 269 AKI survivors followed ≥3 years: 87.4% had complete recovery, 9.7% partial recovery, 3.0% remained dialysis-dependent 6
• However, the concurrent severe hyperbilirubinemia significantly worsens prognosis 4
• Survival of patients with hyperbilirubinemia-associated AKI is significantly lower than AKI from other causes 4

RRT discontinuation criteria 1:

• Kidney function recovery demonstrated by improving creatinine and urine output
• Resolution of life-threatening metabolic derangements
• Ability to maintain fluid balance without RRT
• CPK trending downward (though may remain elevated for weeks)
• Bilirubin decreasing toward <5 mg/dL range

Critical Pitfalls to Avoid

1. Don't delay RRT waiting for CPK to decline: With creatinine 11 mg/dL, the patient needs RRT now regardless of CPK trajectory
2. Don't attribute all AKI to rhabdomyolysis: This patient has dual pathology with hyperbilirubinemia-associated AKI 4
3. Don't stop aggressive fluid resuscitation once RRT starts: Continue fluids while using RRT for volume management
4. Don't treat asymptomatic hypocalcemia aggressively: Risk of calcium-phosphate precipitation in damaged muscle
5. Don't use intermittent hemodialysis if patient is hemodynamically unstable: CRRT is more appropriate 1
6. Don't assume normal CPK rules out myoglobin-induced injury: Delayed presentations can occur with normal CPK 7

Underlying Cause Investigation

Simultaneously investigate:

• Cause of rhabdomyolysis: Trauma, drugs, toxins, infection, prolonged immobilization, compartment syndrome
• Cause of hyperbilirubinemia: Hepatobiliary imaging, hepatitis serologies, drug-induced liver injury, sepsis-related cholestasis
• Compartment syndrome evaluation: If suspected, requires emergent fasciotomy 3

The combination of severe rhabdomyolysis with marked hyperbilirubinemia suggests either severe sepsis, drug toxicity affecting both muscle and liver, or sequential organ failure in a critically ill patient.